ACTG A5142 - PHASE III DRUG THERAPY FOR HIV-1 INFECTION

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。目前的HIV-1感染初始治疗指南为受试者和提供者提供了许多选择。在每一种推荐方案中，大多数新手受试者的病毒学和免疫学参数都有持久的改善。随着新的治疗策略和药物的出现，批判性地评估它们在HIV-1感染管理中的作用是很重要的。本研究将检验洛匹那韦/利托那韦（一种利托那韦增强的第二代蛋白酶抑制剂）为基础的方案、非核苷类逆转录酶抑制剂（NNRTI）为基础的方案和核苷保留方案在HIV-1感染初始治疗中的应用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Current guidelines for the initial treatment of HIV-1 infection provide a number of options to subjects and providers. Durable improvements in virologic and immunologic parameters are observed in the majority of naive subjects for each of the recommended regimens. As newer treatment strategies and drugs become available it is important to critically assess their role in the management of HIV-1 infection. This study will examine the use of a lopinavir/ritonavir (a ritonavir-enhanced, second-generation protease inhibitor)-based regimen, a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, and a nucleoside-sparing regimen for the initial treatment of HIV-1 infection.